JP2014507476A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507476A5
JP2014507476A5 JP2013557816A JP2013557816A JP2014507476A5 JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5 JP 2013557816 A JP2013557816 A JP 2013557816A JP 2013557816 A JP2013557816 A JP 2013557816A JP 2014507476 A5 JP2014507476 A5 JP 2014507476A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
uric acid
gout
composition according
hyperuricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013557816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507476A (ja
JP6012639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/027993 external-priority patent/WO2012125359A1/en
Publication of JP2014507476A publication Critical patent/JP2014507476A/ja
Publication of JP2014507476A5 publication Critical patent/JP2014507476A5/ja
Application granted granted Critical
Publication of JP6012639B2 publication Critical patent/JP6012639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013557816A 2011-03-11 2012-03-07 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 Expired - Fee Related JP6012639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (3)

Publication Number Publication Date
JP2014507476A JP2014507476A (ja) 2014-03-27
JP2014507476A5 true JP2014507476A5 (enExample) 2015-04-23
JP6012639B2 JP6012639B2 (ja) 2016-10-25

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557816A Expired - Fee Related JP6012639B2 (ja) 2011-03-11 2012-03-07 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2555618B1 (en) * 2010-04-08 2015-12-30 TWI Biotechnology, Inc. Methods of using diacerein as an adjunctive therapy for diabetes
WO2012125359A1 (en) 2011-03-11 2012-09-20 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技(武汉)有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
JP2018513203A (ja) * 2015-04-20 2018-05-24 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドTWI Biotechnology, Inc. ジアセレインを含有する製剤及びそれを用いて尿酸の血中濃度を低下させる方法
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
EP3316879A4 (en) 2015-07-01 2019-01-23 TWI Biotechnology, Inc. TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF
CN108349867B (zh) * 2015-08-17 2021-03-09 安成生物科技股份有限公司 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
MX2009004051A (es) * 2006-10-20 2009-05-11 Regeneron Pharma Uso de antagonistas de il-1 para tratar gota y pseudo gota.
EP2471516A3 (en) * 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因(diacerein)之醫藥組合物
WO2012125359A1 (en) 2011-03-11 2012-09-20 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Similar Documents

Publication Publication Date Title
RU2013145498A (ru) Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
Yang et al. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
JP2017513836A5 (enExample)
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
JP2012502015A5 (enExample)
JP2017505285A5 (enExample)
AR082167A1 (es) Formas de dosificacion gastrorretentivas
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
JP2009138003A5 (enExample)
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
JP2018533560A5 (enExample)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
JP2015514797A5 (enExample)
JP2016512817A5 (enExample)
JP2017508817A5 (enExample)
JP2018531273A5 (enExample)
JP2012512164A5 (enExample)
JP2016521279A5 (enExample)
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
JP2016509030A5 (enExample)
JP2019218379A5 (enExample)